Back
 JDM  Vol.7 No.3 , August 2017
Efficacy and Safety of Basal-Supported Prandial GLP-1 Receptor Agonist Therapy
Abstract:
Aim: To assess the safety and efficacy of basal-supported prandial GLP-1 receptor agonist therapy (BPT)* in type 2 diabetes mellitus (T2DM). Methods: Patients with T2DM, who had previously received insulin injection therapy and who had had their treatment switched to BPT (liraglutide), were retrospectively recruited. The efficacy of BPT was assessed by determining changes in HbA1c, body weight and total daily insulin dose from baseline to 4 months after BPT initiation. Safety was assessed by comparing the frequency of hypoglycemic episodes at baseline and after 4 months. The Wilcoxon test was used to analyze changes in parameters throughout the study period. Results: Twenty-nine patients, previously treated with basal-supported oral therapy (BOT), basal-bolus insulin, or pre-mixed insulin, were recruited. When analyzed together, there was no change in HbA1c throughout the study period, but body weight decreased (baseline 68.8 ± 13.2 kg vs. month 4 67.3 ± 13.1 kg; p < 0.001). Total daily insulin dose decreased after 4 months (baseline 24.4 ± 15.5 U/day vs. month 4 14.7 ± 9.2 U/day; p < 0.001), and there was no change in the frequency of hypoglycemic episodes. Analysis was conducted within sub-groups based on previous treatment modality. In the BOT group, HbA1c decreased from baseline after 2 months and body weight did not change throughout the study period. In both the basal-bolus insulin group and the pre-mixed insulin group, HbA1c remained steady throughout and there was a decrease in body weight. No change in the frequency of hypoglycemia was observed in any of the sub-groups. Conclusion: BPT in T2DM was associated with weight loss without changes in glycemic control over 4 months, suggesting that it may be an effective and safe therapy.
Cite this paper: Nagahisa, T. , Tabata, M. and Yamada, S. (2017) Efficacy and Safety of Basal-Supported Prandial GLP-1 Receptor Agonist Therapy. Journal of Diabetes Mellitus, 7, 86-95. doi: 10.4236/jdm.2017.73007.
References

[1]   Ogurtsova, K., da Rocha Femandes, J.D., Huang, Y., Linnenkamp, U., Guariguata, L., cho, N.H., Cavan, D., Shaw, J.E. and Makaroff, L.E. (2017) IDF Diabetes Atlas: Global Estimates for the Prevalence of Diabetes for 2015 and 2040. Diabetes Research and Clinical Practice, 128, 40-50.

[2]   United Kingdom Prospective Diabetes Study Group (1998) United Kingdom Prospective Diabetes Study 24: A 6-Year, Randomized, Controlled Trial Comparing Sulfonylurea, Insulin, and Metformin Therapy in Patients with Newly Diagnosed type 2 Diabetes that Could Not Be Controlled with Diet Therapy. Annals of Internal Medicine, 128, 165-175.

[3]   Ohkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N. and Shichiri, M. (1995) Intensive Insulin Therapy Prevents the Progression of Diabetic Microvascular Complications in Japanese Patients with Non-Insulin-Dependent Diabetes Mellitus: A Randomized Prospective 6-Year Study. Diabetes Research and Clinical Practice, 28, 103-117.
https://doi.org/10.1016/0168-8227(95)01064-K

[4]   United Kingdom Prospective Diabetes Study Group (1998) Intensive Blood-Glucose Control with Sulphonylureas or Insulin Compared with Conventional Treatment and Risk of Complications in Patients with type 2 Diabetes (UKPDS 33). Lancet, 352, 837-853.
ttps://doi.org/10.1016/S0140-6736(98)07019-6

[5]   Shichiri, M., Kishikawa, H., Ohkubo, Y. and Wake, N (2000) Long-Term Results of the Kumamoto Study on Optimal Diabetes Control in Type 2 Diabetic Patients. Diabetes Care, 23(Suppl 2), B21-B29.

[6]   Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., Diamant, M., Ferranini, E., Nauck, M., Peters, A.L., Tsapas, A., Wender, R. and Matthews, D.R. (2012) Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 55, 1577-1596.
https://doi.org/10.1007/s00125-012-2534-0

[7]   Ishii, K., Yamamoto, T. and Ohashi, Y. (2001) Development of QOL Questionnaire (ITR-QOL) about Treatment with Insulin. Diabetes, 44, 17-22.

[8]   Gerstein, H.C., Miller, M.E., Byington, R.P., Goff Jr., D.C., Bigger, J.T., Buse, J.B., Cushman, W.C., Genuth, S., Ismail-Beigi, F., Grimm Jr., R.H., Probstfield, J.L., Simons-Morton, D.G. and Friedewald, W.T. (2008) Effects of Intensive Glucose Lowering in Type 2 Diabetes. The New England Journal of Medicine, 358, 2545-2559.
https://doi.org/10.1056/NEJMoa0802743

[9]   Whitmer, R.A., Karter, A.J., Yaffe, K., Quesenberry Jr., C.P. and Selby, J.V. (2009) Hypoglycemic Episodes and Risk of Dementia in Older Patients with Type 2 Diabetes Mellitus. The Journal of the American Medical Association, 301, 1565-1572.

[10]   Bonds, D.E., Miller, M.E., Bergenstal, R.M., Buse, J.B., Byington, R.P., Cutler, J.A., Dudi, R.J., Ismail-Beigi, F., Kimel, A.R., Hoogwerf, B., Horowitz, K.R., Savafe, P.J., Seaquist, E.R., Simmons, D.L., Sivitz, W.I., Speril-Hillen, J.M. and Sweeney, M.E. (2010) The Association between Symptomatic, Severe Hypoglycaemia and Mortality in Type 2 Diabetes: Retrospective Epidemiological Analysis of the ACCORD Study. British Medical Journal, 340, b4909.
https://doi.org/10.1136/bmj.b4909

[11]   The Japan Diabetes Society (2016) About Management Target Value of the Elderly Diabetes.
http://www.jds.or.jp/modules/important/index.php?page=article&storyid=66_

[12]   Rosenstock, J., Guerci, B., Hanefeld, M., Gentile, S., Aronson, R., Tinahones, F.J., Roy-Duval, C., Souhami, E., Wardecki, M., Ye, J., Perfetti, R. and Heller, S. (2016) Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial. Diabetes Care, 39, 1318-1328.
https://doi.org/10.2337/dc16-0014

[13]   Pfeffer, M.A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H.C., Kober, L.V., Lawson, F.C., Ping, L., Wei, X., Lewis, E.F., Maggioni, A.P., McMurray, J.J., Probstfield, J.L., Riddle, M.C., Solomon, S.D. and Tardif, J.C. (2015) Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. The New England Journal of Medicine, 373, 2247-2257.
https://doi.org/10.1056/NEJMoa1509225

[14]   Marso, S.P., Daniels, G.H., Brown-Frandsen, K., Kristensen, P., Mann, J.F., Nauck, M.A., Nissen, S.E., Pocock, S., Poulter, N.R., Ravn, L.S., Steinberg, W.M., Stockner, M., Zinman, B., Bergenstal, R.M. and Buse, J.B. (2016) Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. The New England Journal of Medicine, 375, 311-322.
https://doi.org/10.1056/NEJMoa1603827

[15]   Ahmann, A.J., Rodbard, H.W., Rosenstock, J., et al. (2015) Efficacy and Safety of Liraglutide versus Placebo Added to Basal Insulin Analogues (with or without Metformin) in Patients with Type 2 Diabetes: A Randomized, Placebo-Controlled Trial. Diabetes, Obesity and Metabolism, 17, 1056-1064.
https://doi.org/10.1111/dom.12539

[16]   Mirna, S., Melanie, K.D., Juris, J. and Michael, A. (2017) A Meta-Analysis Comparing Clinical Effects of Shortor Long-Acting GLP-1 Receptor Agonists Versus Insulin Treatment from Head-to-Head Studies in Type 2 Diebetic Patients. Diabetes, Obesity and Metabolism, 19, 221-222.

[17]   Eng, C., Kramer, C.K., Zinman, B. and Retnakaran, R. (2014) Glucagon-Like Peptide-1 Receptor Agonist and Basal Insulin Combination Treatment for the Management of Type 2 Diabetes: A Systematic Review and Meta-Analysis. Lancet, 384, 2228-2234.
https://doi.org/10.1016/S0140-6736(14)61335-0

 
 
Top